Last reviewed · How we verify
NCT05384509
(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies
trial testing solid organ malignancies treatment in Cancer in 320 participants. Currently enrolling.
28 February 2025
Quick facts
| Lead sponsor | Chang Gung Memorial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 320 |
| Start date | 1 December 2021 |
| Primary completion | 28 February 2025 |
| Estimated completion | 28 February 2025 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- solid organ malignancies treatment
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
Chang Gung Memorial Hospital
Who can join
20 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with cancer are considered vulnerable to severe acute respiratory syndrome coronavirus 2 infection and have been prioritized in the vaccination process in several countries, including Taiwan. In addition, international oncological societies favored COVID-19 vaccination for cancer patients on the basis of risk and benefits evaluation of all available data. However, patients with cancer were excluded from severe acute respiratory syndrome coronavirus 2 vaccines registrational trials and the investigators lack data regarding the safety and efficacy of vaccination in this population. Under this perspective, the investigators undertook a large prospective study enrolling patients with solid cancers, hematologic malignancies as well as healthy volunteers for the kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibodies after COVID-19 vaccination on different anticancer therapy. Major inclusion criteria for this cohort of the study included: (1) age above 20 years; (2) presence of solid organ malignancies treated with immunotherapy, chemotherapy, Targeted therapy irrespective of the treatment phase; and (3) eligibility for vaccination.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.
Vitali L, Merlini A, Galvagno F, Proment A, et al · · 2022 · cited 2× · PMID 36289890 · DOI 10.3390/biomedicines10102628
Verify or expand the search:
- PubMed search for NCT05384509
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Chang Gung Memorial Hospital trials
Trials by the same sponsor.
- NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
- NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
- NCT07036978 — Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer · not yet recruiting
- NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
- NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05384509 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
- Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05384509.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing